apotex-8k_120211.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 2, 2011
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
000-50513
|
|
13-3831168
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
| |
|
|
|
|
| |
|
15 Skyline Drive, Hawthorne, NY
|
|
10532
|
| |
|
(Address of principal executive offices)
|
|
(Zip Code)
|
| |
|
|
|
|
|
Registrant’s telephone number, including area code: (914) 347-4300
|
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On December 2, 2011, Apotex Inc. and Apotex Corp. (collectively, “Apotex”) filed suit against Acorda Therapeutics, Inc. (“Acorda”) in the U.S. District Court for the Southern District of New York. Apotex characterized the suit in its complaint as a “civil antitrust action” and “an action for false advertising” relating to Acorda’s Zanaflex Capsules. Among other allegations, Apotex claims Acorda’s filing of a citizen petition with the U.S. Food and Drug Administration has “delayed FDA approval of Apotex’s generic tizanidine capsules”. The Company intends to defend itself vigorously.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Acorda Therapeutics, Inc.
|
| |
|
|
|
December 7, 2011
|
By:
|
/s/David Lawrence
|
| |
|
Name: David Lawrence
|
| |
|
Title: Chief Financial Officer
|